GenericDrugClaim-logo

GENERIC PHARMACEUTICAL ANTITRUST SETTLEMENTS

Settlement amount: $533,000,000.00

What is it about?

The settlements stems from a long-running federal antitrust class action (In re Generic Pharmaceuticals Pricing Antitrust Litigation, Case No. 16-MD-2724) in the U.S. District Court for the Eastern District of Pennsylvania. End-payers — meaning consumers, insurers, employer health plans, and other entities that paid for or reimbursed prescription generic drugs — alleged that a group of generic drug manufacturers engaged in illegal collusion to artificially inflate prices of certain generic medications sold in the U.S. from May 1, 2009 through December 31, 2019.

Who will be eligible?

A settlement class has been certified for each of the end-payer settlements approved by the court. If, during the class period (2009–2019), you paid for or were reimbursed for one or more of the generic drugs at issue in this litigation, you may be a Settlement Class Member. The settlement class definitions and the list of eligible drugs (many dozens) is contained in the settlement notices posted on the official settlement site www.GenericDrugsEndPayerSettlement.com

Settlement Classes To Date Include

  • Sandoz / Fougera Settlement – Resolves end-payer antitrust claims against Sandoz and Fougera by creating a cash fund (approximately $275M) to compensate eligible consumers and third-party payors for alleged generic-drug price inflation during the class period, with no admission of wrongdoing.
  • Apotex / Heritage Settlement – Resolves claims against Apotex for approximately $48 million and against Heritage Pharmaceuticals for $10 million to be paid to third party payers.
  • Sun / Taro Settlement – Resolves end-payer claims against Sun Pharmaceutical Industries and Taro Pharmaceuticals by establishing a $200 million settlement fund, to be paid to consumers and third party payers.